drugset / Trial / NCT00634790

A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks

NCT00634790

Phase 4 Terminated 49 enrolled Viatris Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the long-term safety and tolerability of alprazolam extended release (XR) in adolescents with panic disorder, with or without agoraphobia, or in anxiety disorder with panic attacks. Efficacy, population pharmacokinetics of alprazolam XR and the relationship between alprazolam XR plasma concentrations and efficacy outcomes will also be evaluated.

Timeline

Start
2004-05
Primary completion
Completion
2004-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alprazolam Small molecule 6 mg Oral

Indications